
Sign up to save your podcasts
Or


There are a few Australians greater than Professor Richard Scolyer.
As co-director of the Melanoma Institute of Australia, he led the charge in creating immunotherapy, which is a treatment for deadly melanoma skin cancers, that supercharges the body’s immune system to destroy cancer cells.
The treatment led to him being honoured as being one of the two Austrlaians of the year in 2024.
Everything changed after he was diagnosed with an incurable brain cancer in 2023.
Not going to accept the status quo, he chose to undertake a world-first experimental treatment based on melanoma science.
And he survived.
Luke Grant chats with Professor Richard Scolyer to hear his story and chat about his new book, Brainstorm, and his upcoming talk at the Sydney Opera House. You can order a copy of ‘Brainstorm’ here
See omnystudio.com/listener for privacy information.
By 2GBThere are a few Australians greater than Professor Richard Scolyer.
As co-director of the Melanoma Institute of Australia, he led the charge in creating immunotherapy, which is a treatment for deadly melanoma skin cancers, that supercharges the body’s immune system to destroy cancer cells.
The treatment led to him being honoured as being one of the two Austrlaians of the year in 2024.
Everything changed after he was diagnosed with an incurable brain cancer in 2023.
Not going to accept the status quo, he chose to undertake a world-first experimental treatment based on melanoma science.
And he survived.
Luke Grant chats with Professor Richard Scolyer to hear his story and chat about his new book, Brainstorm, and his upcoming talk at the Sydney Opera House. You can order a copy of ‘Brainstorm’ here
See omnystudio.com/listener for privacy information.

7 Listeners

20 Listeners

82 Listeners

19 Listeners

4 Listeners

10 Listeners

0 Listeners

1 Listeners

2 Listeners

4 Listeners

53 Listeners

302 Listeners

6 Listeners

5 Listeners

1 Listeners

5 Listeners

4 Listeners

1 Listeners

1 Listeners

52 Listeners

13 Listeners

227 Listeners

0 Listeners

2 Listeners

0 Listeners